NuCana (NCNA) Competitors $1.54 -0.08 (-4.94%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NCNA vs. AKTX, IPA, BFRG, COCP, TXMD, SLGL, MEIP, ATHA, HCWB, and NERVShould you be buying NuCana stock or one of its competitors? The main competitors of NuCana include Akari Therapeutics (AKTX), ImmunoPrecise Antibodies (IPA), Bullfrog AI (BFRG), Cocrystal Pharma (COCP), TherapeuticsMD (TXMD), Sol-Gel Technologies (SLGL), MEI Pharma (MEIP), Athira Pharma (ATHA), HCW Biologics (HCWB), and Minerva Neurosciences (NERV). These companies are all part of the "pharmaceutical products" industry. NuCana vs. Akari Therapeutics ImmunoPrecise Antibodies Bullfrog AI Cocrystal Pharma TherapeuticsMD Sol-Gel Technologies MEI Pharma Athira Pharma HCW Biologics Minerva Neurosciences Akari Therapeutics (NASDAQ:AKTX) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability, earnings and community ranking. Does the MarketBeat Community favor AKTX or NCNA? Akari Therapeutics received 11 more outperform votes than NuCana when rated by MarketBeat users. However, 67.65% of users gave NuCana an outperform vote while only 52.30% of users gave Akari Therapeutics an outperform vote. CompanyUnderperformOutperformAkari TherapeuticsOutperform Votes26252.30% Underperform Votes23947.70% NuCanaOutperform Votes25167.65% Underperform Votes12032.35% Which has higher valuation & earnings, AKTX or NCNA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$10.01MN/AN/ANuCanaN/AN/A-$34.37M-$12.20-0.13 Is AKTX or NCNA more profitable? Akari Therapeutics' return on equity of 0.00% beat NuCana's return on equity.Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A N/A N/A NuCana N/A -222.73%-105.62% Do insiders & institutionals have more ownership in AKTX or NCNA? 5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 38.9% of Akari Therapeutics shares are owned by company insiders. Comparatively, 31.2% of NuCana shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, AKTX or NCNA? Akari Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, NuCana has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500. Do analysts prefer AKTX or NCNA? NuCana has a consensus price target of $25.00, indicating a potential upside of 1,523.38%. Given NuCana's higher probable upside, analysts plainly believe NuCana is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ANuCana 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media favor AKTX or NCNA? In the previous week, Akari Therapeutics had 2 more articles in the media than NuCana. MarketBeat recorded 2 mentions for Akari Therapeutics and 0 mentions for NuCana. Akari Therapeutics' average media sentiment score of 0.00 equaled NuCana'saverage media sentiment score. Company Overall Sentiment Akari Therapeutics Neutral NuCana Neutral SummaryAkari Therapeutics beats NuCana on 6 of the 11 factors compared between the two stocks. Ad Crypto 101 MediaMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…All you have to do is claim your free ticket to the event now… Get NuCana News Delivered to You Automatically Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NCNA vs. The Competition Export to ExcelMetricNuCanaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.07M$7.02B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.139.42113.4615.10Price / SalesN/A385.111,484.4093.54Price / CashN/A47.3339.6434.05Price / Book0.175.324.655.02Net Income-$34.37M$153.56M$119.06M$225.46M7 Day Performance-13.97%0.12%0.79%0.37%1 Month Performance-23.76%15.23%5.65%3.57%1 Year Performance-87.17%41.16%36.76%29.42% NuCana Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NCNANuCana3.0979 of 5 stars$1.54-4.9%$25.00+1,523.4%-86.9%$4.07MN/A-0.1330Positive NewsAKTXAkari TherapeuticsN/A$2.36+4.0%N/A-22.6%$18.74MN/A0.009Analyst ForecastNews CoverageGap UpIPAImmunoPrecise Antibodies2.5622 of 5 stars$0.68+17.3%$6.00+784.8%-80.3%$18.51M$18.16M-0.8780Gap DownHigh Trading VolumeBFRGBullfrog AI1.19 of 5 stars$2.35+3.5%N/A-14.9%$18.45M$65,000.00-2.804Gap UpCOCPCocrystal Pharma2.7036 of 5 stars$1.81-7.2%$7.00+286.7%+4.2%$18.42MN/A-1.0210Positive NewsTXMDTherapeuticsMD0.8331 of 5 stars$1.59+0.6%N/A-26.1%$18.34M$996,000.000.00420SLGLSol-Gel Technologies2.4697 of 5 stars$0.65flat$5.00+664.6%-60.8%$18.22M$6.56M-1.2150Gap UpMEIPMEI Pharma4.567 of 5 stars$2.73flat$7.00+156.4%-56.3%$18.18M$65.30M1.02100Analyst ForecastNews CoverageGap DownHigh Trading VolumeATHAAthira Pharma2.5581 of 5 stars$0.47-2.1%$13.83+2,857.1%-65.4%$17.93MN/A-0.1640Gap UpHCWBHCW Biologics1.1279 of 5 stars$0.46-8.0%N/A-73.0%$17.49M$3.92M-0.4440Short Interest ↓Gap UpNERVMinerva Neurosciences4.0737 of 5 stars$2.44-0.8%$5.00+104.9%-47.6%$17.06MN/A-0.559Upcoming EarningsAnalyst ForecastNews Coverage Related Companies and Tools Related Companies Akari Therapeutics Competitors ImmunoPrecise Antibodies Competitors Bullfrog AI Competitors Cocrystal Pharma Competitors TherapeuticsMD Competitors Sol-Gel Technologies Competitors MEI Pharma Competitors Athira Pharma Competitors HCW Biologics Competitors Minerva Neurosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NCNA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana plc Please log in to your account or sign up in order to add this asset to your watchlist. Share NuCana With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
